Siga este link para ver outros tipos de publicações sobre o tema: Theophylline.

Artigos de revistas sobre o tema "Theophylline"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Theophylline".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Tatsis, G., J. Danos, M. Gaga, D. Pantelakis, M. Veslemes e J. Jordanoglou. "A Single-Blind Crossover Study of Two Different Slow Release Theophylline Preparations". Journal of International Medical Research 16, n.º 6 (novembro de 1988): 452–58. http://dx.doi.org/10.1177/030006058801600607.

Texto completo da fonte
Resumo:
In a single-blind crossover study, two slow release theophylline preparations were evaluated in 18 patients with chronic bronchitis or asthma without cardiac, renal or liver disease. After randomization into two groups, patients were treated, in a crossover study design, with 600 mg choline theophyllinate or 300 mg anhydrous theophylline administered orally every 12 h for 7 days. A 2-day washout period separated the two periods of treatment evaluation. Blood samples in which plasma theophylline concentration was to be measured were taken at 7.30 a.m., 2.00 p.m. and 7.30 p.m. during the last 5 days of therapy with each drug. The mean fluctuation in plasma theophylline concentration was ≤40% in all 18 patients taking choline theophyllinate yet in only 15 (83%) patients administered anhydrous theophylline. Salbutamol inhaler was more frequently required for the relief of bronchospasm when taking anhydrous theophylline than when taking choline theophyllinate (total of 41 vs 25 puffs, respectively, over 7 days). Drug-related adverse reactions occurred in four patients while taking anhydrous theophylline and in one patient while taking choline theophyllinate.
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Ali, Tasneem Basheer, Huda Yousef Almomani, Fatima Mahmoud Al-Tarawneh, Maysa Waddah Alwadi e Ahmad Shaher Suliman. "Physicians' Knowledge of Theophylline Use: A Cross-Sectional Study from Jordan". Jordan Journal of Pharmaceutical Sciences 16, n.º 4 (25 de dezembro de 2023): 857–70. http://dx.doi.org/10.35516/jjps.v16i4.1789.

Texto completo da fonte
Resumo:
Objective: This cross-sectional study aims to assess physicians' knowledge regarding theophylline drug and other related characteristics in Jordan. Materials and Method: The study was conducted prospectively among physicians in Jordan. Physicians were interviewed using an online questionnaire consisting of two sections. The first section included demographics and other relevant characteristics, while the second section comprised questions about theophylline drug. Results: A total of 385 participants completed the questionnaire. The majority of participants knew that theophylline is used in clinical practice as a bronchodilator (75.6%). Nearly 39% of participants knew that theophylline can be administered orally and intravenously. The largest share of participants (76.1%) did not know that theophylline dosage is calculated based on ideal body weight. Sixty percent of participants knew that theophylline use was not contraindicated during pregnancy. On the other hand, only 27.3% knew that theophylline use was not contraindicated during breastfeeding. The majority of participants (76.1%) had an overall intermediate knowledge of theophylline. Conclusions: It was noted that physicians had an overall intermediate knowledge of theophylline. Physicians demonstrated unsatisfactory knowledge about theophylline’s indications, clinical use, administration, adverse effects, and other related aspects. These findings highlight the need for educational interventions and training programs to improve physicians’ knowledge of theophylline and enhance its effective and safe use in clinical practice.
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Malamatari, Maria. "Inhaled theophylline: old drug new tricks?" International Journal of Basic & Clinical Pharmacology 13, n.º 1 (26 de dezembro de 2023): 174–80. http://dx.doi.org/10.18203/2319-2003.ijbcp20233912.

Texto completo da fonte
Resumo:
Theophylline and aminophylline (i.e., the soluble complex of theophylline with ethylenediamine) have been used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease for more than 90 years. Theophylline’s narrow therapeutic index and side effects, as well as the discovery of more potent and safer bronchodilators, made it to fall out of favour with healthcare professionals and patients. New scientific knowledge on the molecular mechanism of action of theophylline, along with increasing clinical evidence suggest that theophylline should be exploited as an anti-inflammatory agent rather than a bronchodilator. This review covers the journey of theophylline from rise to fall and back to its potential re-emergence as a combination formulation with inhaled corticosteroids in the management of chronic inflammatory lung diseases. Several approaches to formulate theophylline either as a monotherapy or as a combination therapy for delivery to the lungs are presented.
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Boner, A. L., G. De Stefano, G. Vallone, M. Plebani e P. Ventura. "Absolute and Relative Bioavailability of a Slow Release Theophylline Preparation in Asthmatic Children". Journal of International Medical Research 15, n.º 5 (setembro de 1987): 282–92. http://dx.doi.org/10.1177/030006058701500504.

Texto completo da fonte
Resumo:
This study was carried out on 14 asthmatic childen aged 7–13 years. They all received three preparations (aminophylline by intravenous infusion, lysine theophyllinate orally in solution and slow release theophylline orally as capsules) in a single dose of 100 mg active ingredient in a crossover design. Plasma theophylline concentrations, determined by a fluorescent polarization immunoassay, were evaluated both by compartmental and non-compartmental analysis. After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (± SD) 3.19 ± 0.63 μg/ml and 8.71 ± 2.30 h, respectively, compared to 4.51 ± 0.94 μg/ml and 1.96 ± 0.85 h, respectively, for the oral normal release solution. Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (± SD) 92.7 ± 23.2% and 83.14 ± 14.69%, respectively. These are similar to the values found with other slow release formulations in paediatric patients.
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

BRODWALL, ERLING K. "The Resorption of Theophyllamine (Theophylline Ethylenediamine)". Acta Medica Scandinavica 146, n.º 2 (24 de abril de 2009): 123–26. http://dx.doi.org/10.1111/j.0954-6820.1953.tb10222.x.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Nolte, Matthias, Ingo Pantenburg e Gerd Meyer. "Konkurrierende Liganden: Theophyllin als nicht- und stark koordinierender Ligand in Quecksilber(II)-Komplexen / Competing Ligands: Theophylline as Non- and Strongly Coordinating Ligand in Mercury(II) Complexes". Zeitschrift für Naturforschung B 61, n.º 6 (1 de junho de 2006): 758–65. http://dx.doi.org/10.1515/znb-2006-0617.

Texto completo da fonte
Resumo:
[{Hg(CF3)2}(ThpH)(H2O)](H2O) (1), [{Hg4(Thp)4}(ClO4)4(H2O)8](H2O)4 (2), [{Hg(ThpH)2} (NO3)](NO3) (3) and {Hg(Thp)Cl}(H2O) (4) (ThpH = theophylline, C7H8N4O2) have been synthesized by slow evaporation of aqueous solutions of the mercuric salts Hg(CF3)2, Hg(ClO4)2, Hg(NO3)2, or HgCl2 and theophylline. Their crystal structures were determined on the basis of single crystal X-ray data. The coordination polymers 1 and 2 crystallize with triclinic symmetry, P1̅ (no. 2), with a = 468.8(2), b = 1256.4(5), c = 1445.5(6) pm, α = 67.15(3), β = 89.21(3), γ = 89.40(3)° and a = 833.6(1), b = 1862.7(2), c = 2182.9(2) pm, α = 111.61(1), β = 90.98(1), γ = 95.51(1)°, respectively. 3 and 4 crystallize with monoclinic symmetry, Pc (no. 7), a =1194.1(1), b=1258.8(2), c=735.5(2) pm, β =96.96(2)° and P21/n (no. 14), a=1069.0(2), b =911.6(1), c=1089.9(2) pm and β = 96.87(2)°. In 1 the theophylline molecules are non-coordinating to mercury and leave the Hg(CF3)2 molecule unchanged. Only weak electrostatic attractions to one keto-oxygen atom of theophylline and one water molecule hold this co-crystallisate together. In 2, the theophyllinate anion, Thp−, strongly coordinates with both N(7) and N(9) to HgII forming a large ring with eight Hg atoms that incorporates the water molecules. One sort of nitrate ions in 3 is weakly attached to HgII with the theophylline molecules still bound strongly through N(9). The chloride ligand and the theophyllinate ion seem to have the same strengths as ligands in 4 as they are both attached to HgII with the shortest distances possible
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Wang, L. C., S. F. Man e A. N. Belcastro. "Metabolic and hormonal responses in theophylline-increased cold resistance in males". Journal of Applied Physiology 63, n.º 2 (1 de agosto de 1987): 589–96. http://dx.doi.org/10.1152/jappl.1987.63.2.589.

Texto completo da fonte
Resumo:
The effects of theophylline (a phosphodiesterase inhibitor-adenosine receptor antagonist) and substrate feeding (Ensure, 250 kcal/235 ml) on cold resistance were studied in seminude males undertaking submaximal (50% maximum O2 consumption), intermittent (34% of total time) exercise in the cold (-5 to 15 degrees C, individually adjusted) for 3 h. Each subject (n = 7) served as his own control and was tested on a weekly schedule. Under control treatment, rectal temperature (Tre) decreased by 0.9 degrees C to approximately 36.2 degrees C after cold exposure, whereas under theophylline and Ensure, the decrease of Tre was only 0.4 degrees C, indicating a significant increase (P less than 0.05) in cold resistance (50% better than control). The plasma concentration of theophylline was 4.8–5.9 micrograms/ml and was positively correlated with plasma concentration of free fatty acids. Plasma norepinephrine (NE) increased significantly during cold exposure; the absolute concentration was significantly higher after theophylline pretreatment. The plasma concentrations of glucose, epinephrine, cortisol, and adenosine 3′,5′-cyclic monophosphate did not change and the changes of free thyroxine and triiodothyronine were minor. Together, the effectiveness of theophylline + Ensure in acutely increasing cold resistance may be due to increased substrate availability for thermogenesis, part of which, through theophylline's potentiation of both sympathetic release of NE and NE-stimulated lipolysis and part of which, through supplementary feeding of Ensure.
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Jeong, Chan Su, Soon Chul Hwang, Daniel W. Jones, Hwan Sun Ryu, Kieho Sohn e Charles D. Sands. "Theophylline Disposition in Korean Patients with Congestive Heart Failure". Annals of Pharmacotherapy 28, n.º 3 (março de 1994): 396–401. http://dx.doi.org/10.1177/106002809402800319.

Texto completo da fonte
Resumo:
OBJECTIVE: This study proposed to determine the systemic disposition on of theophyllinein Korean adult patients during decompensated congestive heart failure compared with disposition after recovery. DESIGN: An experimental, prospective, self-controlled, non randomized design was used. SETTING: The study was performed in a general communityhospital located in Pusan, Korea. PATIENTS: Eight nonsmoking elderly Korean patients with decompensated congestive heart failure presenting to the emergency department were included in the study. Consecutive patients who met entrance criteria were selected. All patients completed the study. INTERVENTIONS: A single dose of aminophylline 6 mg/kg was administered by intravenous infusion over 30 minutes. Standard methods of congestive heart failure therapy were used in each patient, including bed rest, restriction of sodium, and drug therapy including digoxin. After compensation of congestive heart failure was achieved the theophylline infusion was repeated. OUTCOME MEASURES: Serum theophylline concentrations were measured at 2, 6, 12, and 18 hours after completion of the dose at base line and following treatment. RESULTS: A clinically and statistically significant improvement in mean theophylline total body clearance was demonstrated following treatment (from 21.7 ± 2.8 to 43.4 ± 4.7 mL/kg/h [mean ± SEM]; p<0.01). Comparison of these results with a computer model based on literature averages of peoples of all nationalities showed significant underprediction of theophylline clearance both before (p<0.05)and after (p<0.01) treatment. The theophylline elimination half-life prior to treatment was 18.2 ± 2.2 hours and decreased to 9.1 ± 0.8 hours following treatment(p<0.O1). There was no statistical difference between the computer-model predicted initial theophylline half-life and the measured value, but the model significantly underpredicted the improvement following treatment. CONCLUSIONS: The improvement in theophylline clearance demonstrated in this study appears to be greater than that reported for Western patients. This has practical application to the calculation of appropriate theophylline maintenance dosage regimens in Korean patients with cardiac failure. These data support the need for consideration of racial differences in individualizing dosage regimens. We suggest that all kinetic models, whether software supported or not, should consider incorporating ethnic origin as a demographic factor that helps select the proper model for individual patients.
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Rees, Sharon. "THEOPHYLLINE". Journal of Prescribing Practice 3, n.º 2 (2 de fevereiro de 2021): 52. http://dx.doi.org/10.12968/jprp.2021.3.2.52.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 728 (novembro de 1998): 12. http://dx.doi.org/10.2165/00128415-199807280-00041.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
11

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 1167 (setembro de 2007): 26. http://dx.doi.org/10.2165/00128415-200711670-00078.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
12

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 1152 (maio de 2007): 25–26. http://dx.doi.org/10.2165/00128415-200711520-00078.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
13

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 1371 (outubro de 2011): 35–36. http://dx.doi.org/10.2165/00128415-201113710-00130.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
14

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 533 (janeiro de 1995): 11. http://dx.doi.org/10.2165/00128415-199505330-00042.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
15

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 544 (abril de 1995): 12. http://dx.doi.org/10.2165/00128415-199505440-00035.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
16

Napier‐Flood, Fiona E., e Brian R. Creese. "Theophylline". Medical Journal of Australia 162, n.º 10 (maio de 1995): 548–50. http://dx.doi.org/10.5694/j.1326-5377.1995.tb138519.x.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
17

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 433 (janeiro de 1993): 11. http://dx.doi.org/10.2165/00128415-199304330-00048.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
18

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 446 (abril de 1993): 12. http://dx.doi.org/10.2165/00128415-199304460-00053.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
19

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 452 (maio de 1993): 11. http://dx.doi.org/10.2165/00128415-199304520-00051.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
20

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 458 (julho de 1993): 11. http://dx.doi.org/10.2165/00128415-199304580-00057.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
21

Barnes, Peter J. "Theophylline". Pharmaceuticals 3, n.º 3 (18 de março de 2010): 725–47. http://dx.doi.org/10.3390/ph3030725.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
22

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 621 (outubro de 1996): 12. http://dx.doi.org/10.2165/00128415-199606210-00041.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
23

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 627 (novembro de 1996): 12. http://dx.doi.org/10.2165/00128415-199606270-00036.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
24

Weinberger, Miles M. "Theophylline". Immunology and Allergy Clinics of North America 10, n.º 3 (agosto de 1990): 559–76. http://dx.doi.org/10.1016/s0889-8561(22)00295-8.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
25

Milgrom, Henry. "THEOPHYLLINE". Immunology and Allergy Clinics of North America 13, n.º 4 (novembro de 1993): 819–38. http://dx.doi.org/10.1016/s0889-8561(22)00662-2.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
26

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 791 (março de 2000): 12. http://dx.doi.org/10.2165/00128415-200007910-00029.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
27

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 369 (setembro de 1991): 11. http://dx.doi.org/10.2165/00128415-199103690-00060.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
28

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 371 (outubro de 1991): 12. http://dx.doi.org/10.2165/00128415-199103710-00061.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
29

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 374 (outubro de 1991): 8. http://dx.doi.org/10.2165/00128415-199103740-00042.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
30

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 380 (dezembro de 1991): 8. http://dx.doi.org/10.2165/00128415-199103800-00041.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
31

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 384 (janeiro de 1992): 12. http://dx.doi.org/10.2165/00128415-199203840-00065.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
32

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 403 (maio de 1992): 8. http://dx.doi.org/10.2165/00128415-199204030-00034.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
33

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 1199 (abril de 2008): 44. http://dx.doi.org/10.2165/00128415-200811990-00134.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
34

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 1214 (agosto de 2008): 29. http://dx.doi.org/10.2165/00128415-200812140-00084.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
35

Markham, Anthony, e Diana Faulds. "Theophylline". Drugs 56, n.º 6 (1998): 1081–91. http://dx.doi.org/10.2165/00003495-199856060-00018.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
36

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 915 (agosto de 2002): 12. http://dx.doi.org/10.2165/00128415-200209150-00040.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
37

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 296 (abril de 1990): 7. http://dx.doi.org/10.2165/00128415-199002960-00032.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
38

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 307 (junho de 1990): 7. http://dx.doi.org/10.2165/00128415-199003070-00034.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
39

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 313 (agosto de 1990): 8. http://dx.doi.org/10.2165/00128415-199003130-00042.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
40

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 328 (novembro de 1990): 11. http://dx.doi.org/10.2165/00128415-199003280-00059.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
41

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 341 (março de 1991): 11. http://dx.doi.org/10.2165/00128415-199103410-00067.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
42

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 347 (abril de 1991): 7. http://dx.doi.org/10.2165/00128415-199103470-00033.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
43

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 356 (junho de 1991): 8. http://dx.doi.org/10.2165/00128415-199103560-00037.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
44

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 359 (julho de 1991): 8. http://dx.doi.org/10.2165/00128415-199103590-00042.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
45

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 364 (agosto de 1991): 12. http://dx.doi.org/10.2165/00128415-199103640-00058.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
46

Nasser, Shuaib S. M., e P. John Rees. "Theophylline". Drug Safety 8, n.º 1 (janeiro de 1993): 12–18. http://dx.doi.org/10.2165/00002018-199308010-00003.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
47

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 506 (junho de 1994): 12. http://dx.doi.org/10.2165/00128415-199405060-00063.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
48

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 510 (julho de 1994): 12. http://dx.doi.org/10.2165/00128415-199405100-00056.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
49

&NA;. "Theophylline". Reactions Weekly &NA;, n.º 1334 (janeiro de 2011): 43. http://dx.doi.org/10.2165/00128415-201113340-00153.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
50

Svedmyr, Nils. "Theophylline". American Review of Respiratory Disease 136, n.º 4_pt_2 (outubro de 1987): S68—S71. http://dx.doi.org/10.1164/ajrccm/136.4_pt_2.s68.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!

Vá para a bibliografia